Oral small molecule GLP-1 receptor agonist
HRS-7535 60 mg tablet once daily
HRS7535_PO_60MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -1.27 (-11.67 to 9.18) | 0.32 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.38 (-10.79 to 2.72) | 0.37 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.11 (-10.35 to 3.21) | 0.29 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.84 (0.20 to 16.79) | 0.39 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.83 (0.10 to 25.86) | 0.50 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.90 (2.06 to 20.83) | 0.29 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.86 (2.11 to 29.61) | 0.33 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.32 (0.73 to 7.58) | 0.42 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.29 (0.38 to 49.95) | 0.30 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.43 (0.00 to 15.98) | 0.72 |